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Synthetic preimplantation factor 
(spif) induces posttranslational 
protein modification and reverses 
paralysis in eAe mice
Soren Hayrabedyan  1, Reut Shainer2,3, Zhanna Yekhtin2, Lola Weiss2, osnat Almogi-
Hazan2, Reuven or2, charles L. farnsworth4, Scott newsome5, Krassimira Todorova1, 
Michael J. paidas6,7, chaya Brodie8,9, eytan R. Barnea10,11 & Martin Mueller  6,12,13
An autoimmune response against myelin protein is considered one of the key pathogenic processes 
that initiates multiple sclerosis (MS). The currently available MS disease modifying therapies have 
demonstrated to reduce the frequency of inflammatory attacks. However, they appear limited in 
preventing disease progression and neurodegeneration. Hence, novel therapeutic approaches targeting 
both inflammation and neuroregeneration are urgently needed. A new pregnancy derived synthetic 
peptide, synthetic PreImplantation Factor (sPIF), crosses the blood-brain barrier and prevents neuro-
inflammation. We report that sPIF reduces paralysis and de-myelination of the brain in a clinically-
relevant experimental autoimmune encephalomyelitis mice model. These effects, at least in part, are 
due to post-translational modifications, which involve cyclic AMP dependent protein kinase (PKA), 
calcium-dependent protein kinase (pKc), and immune regulation. in terms of potential MS treatment, 
sPIF was successfully tested in neurodegenerative animal models of perinatal brain injury and 
experimental autoimmune encephalitis. Importantly, sPIF received a FDA Fast Track Approval for first in 
human trial in autommuninty (completed).
An autoimmune response against myelin protein is considered one of the key pathogenic processes that initi-
ates multiple sclerosis (MS). In MS, trafficking of the peripherally activated myelin reactive T cells across the 
blood-brain barrier initiate an immune cascade leading to acute and chronic inflammation, de-myelination, 
and axonal injury resulting in neurodegeneration1. The currently available MS disease modifying therapies have 
demonstrated in studies to reduce the frequency of inflammatory attacks; however, they appear limited in pre-
venting disease progression and neurodegeneration2. Novel therapeutic approaches addressing both inflamma-
tion and neuroregeneration are urgently needed. One approach is modulation of cyclic AMP dependent protein 
kinase (PKA) and calcium-dependent protein kinase (PKC) kinases3. PKA/PKC are important signaling mole-
cules in a variety of cellular functions, including neuronal plasticity, cell growth and differentiation, and cellular 
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response to hypoxia-ischemia4,5. Interestingly, modulation of PKC signaling leads to an unconventional commu-
nication between the immune system and nervous system with IL-4 preventing axon pathology and leading to 
functional recovery6. Given the emerging importance of PKA/PKC in neurodegenerative disorders3 along with 
synthetic PreImplantation Factor (sPIF) modulating PKA/PKC7, we aimed to evaluate sPIF in the experimental 
autoimmune encephalomyelitis (EAE) model.
PIF is a small peptide detectable in the maternal circulation during pregnancy and associated with viable 
embryo8,9. Endogenous PIF is involved with embryo implantation by modulating maternal immune tolerance10,11. 
A synthetic analog of natural PIF (sPIF) prevented paralysis and restored spinal myelination through inhibiting 
neuro-inflammation in murine models of EAE12,13. The potential of sPIF therapy for Alzheimer’s Disease was 
previously reported14 and sPIF’s ability to reduce neuronal loss and microglial activation in a murine model of 
perinatal brain injury provides further evidence of sPIF’s putative neuroprotective properties7,15. Here, we report 
that sPIF induces global posttranslational protein modifications in the brain, while preserving brain myelin in 
the EAE animal model. Further, these effects are, at least in part, due to changes of cyclic AMP dependent protein 
kinase (PKA) and calcium-dependent protein kinase (PKC) kinase after sPIF treatment. These effects appear 
in line with PIF’s pleiotropic function both in and outside pregnancy16 such as seen in autoimmune diabetes17, 
atherosclerosis18, graft versus host disease19, and radiation induced pathologies20. In terms of MS, sPIF could be 
useful as a treatment especially since sPIF crosses the blood-brain barrier and has successfully been tested in 
animal models of brain injury and inflammation7,15. sPIF received a FDA Fast Track Approval for first in human 
trial in autoimmune hepatitis.
Results
sPIF reverses myelination deficits. Given that sPIF protected the spinal cord in the EAE model previ-
ously12 we sought to evaluate if similar neuroprotective effects occurred on the brain. We aimed to mimic the 
relapsing remitting MS therapy by episodic sPIF treatments. We used sPIF subcutaneously, glatiramer acetate 
(GA), and PBS once paralysis developed (≥score 1) and continued until paralysis regressed. In order to have a 
short and long-term follow up we analyzed the main outcome at three time-points. As shown in Table 1, sPIF 
reduced the clinical scores compared to PBS (EAE) and GA treated (EAE + GA) mice and at time point 3 sPIF 
was most effective (Fig. 1A and Table 1 – Time Point 3). As MS tends to be progressive leading to chronic dis-
ease of the spine and brain white matter21, we chose time point 3 brain tissues for further analyses. Indeed, EAE 
resulted in loss of myelin in the subcortical white matter tracts, which was specifically evident in the corpus 
callosum (Fig. 1B see red arrows). GA treatment resulted in partial re-myelination, which is in line with the 
modestly improved EAE clinical scores (Fig. 1B,C and Table 1). Importantly, sPIF treatment resulted in reduced 
brain de-myelination that closely resemble controls (Fig. 1B,C: compare green to red and black bars), which was 
in parallel with the observed improved clinical scores (Table 1). Together, sPIF treatment results in clinical and 
histological reduction of white matter loss in an EAE animal model.
spif induces global phosphorylation changes in the brain. To better understand the sPIF-induced 
changes (Fig.  1), we selected a global screening approach using antibody-based enrichment from 
well-characterized post-translational modifications (PTMs)7,22. These antibodies detect targeted PTMs in the 
context of specific binding motif or substrate and therefore present a global overview of induced changes. In 
order to identify specific changes, we combined the antibody-based immunoprecipitation PTMs enrichment with 
liquid chromatography-tandem mass spectrometry (Orbitrap LQ-MS). We excluded GA-treated EAE mice, as the 
treatment was not superior to sPIF (Table 1 and Fig. 1). As seen in the Whisker box plots (Fig. 2A) EAE resulted in 
an increased global (normalized) abundance of significantly expressed phosphoproteins and with sPIF treatment 
this abundance was decreased. We confirmed these observations using unsupervised hierarchical clustering of 
phosphoproteins (Fig. 2B – heat map). Notably, we aimed to cover highly diverse regulatory pathways using a 
novel combination of phospho-Ser/Thr motif antibodies to provide broader coverage of the phosphoproteome23. 
Mean Clinical Score Peak Paralysis Mean Clinical Score End
Time Point 1 26 days
EAE 1.36 ± 0.22 2.5 ± 0.33 1.3 ± 0.44
EAE + GA 1.3 ± 0.15 2.4 ± 0.33 1.6 ± 0.44
EAE + sPIF 0.95 ± 0.19 2.1 ± 0.23 *0.60 ± 0.22
Time Point 2 41 days
EAE 1.01 ± 0.19 1.0 ± 0.28 1 ± 0
EAE + GA 0.80 ± 0.11 1.85 ± 0.23 1.4 ± 0.6
EAE + sPIF *0.45 ± 0.08 0.91 ± 0.14 *0.5 ± 0.18
Time Point 3 50 days
EAE 2.6 ± 0.20 4.37 ± 0.18 2.12 ± 0.85
EAE + GA 2.4 ± 0.15 4.33 ± 0.16 2.44 ± 0.53
EAE + sPIF *1.2 ± 0.10 *3 ± 0.33 *0.66 ± 0.55
Table 1. Clinical scores in the EAE model after GA and sPIF treatments. Clinical score analysis of sPIF and 
GA at the three different time points in EAE mice. We ended the experiment at Time Point 1: 26 days, Time 
Point 2: 41 days, and Time Point 3: 50 days. For further analyses we selected Time Point 3 as the effect of sPIF 
was profound. MCS = mean clinical score, PP = peak paralysis, MCE = mean clinical score end. sPIF: synthetic 
PreImplantation Factor; GA: glatiramer acetate. EAE: experimental autoimmune encephalomyelitis. Data is 
expressed as mean +/− SEM. sPIF, GA and PBS: n = 7–18 per group. *p < 0.05 compared to EAE. Control 
(healthy animals) are not presented as the score was 0.
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Using this screening approach, we detected changes of cyclic AMP dependent protein kinase (PKA) and 
calcium-dependent protein kinase (PKC) kinase after sPIF treatment (Fig. 2C,D). Notably, PKA/PKC are impor-
tant signaling molecules in a variety of cellular functions, including neuronal plasticity or cell growth and differ-
entiation4,5. Modulation of PKA/PKC in MS was previously reported1,3. The detailed analysis and clustering of 
the significantly modulated proteins is summarized in Tables 2 and 3 and as expected, both EAE and sPIF mod-
ulated multiple phosphoproteins. To put the induced interactions into context, we used PhosphoSitePlus derived 
Kinase-Substrate data in combination with gene-enrichment and network linkage analysis of phosphoprotein 
expression data (Fig. 3A). We detected multiple changes and cAMP-dependent protein kinases, with catalytic 
Figure 1. sPIF reduces clinical severity and de-myelination in EAE mice. We induced EAE in mice and started 
sPIF, GA, or PBS episodically once paralysis developed. (A) We monitored and assessed paralysis scores in 
mice until day 50. In Table 1 we describe detailed scores and additional time points. (B) At day 50 we assessed 
brain myelination using Luxol Fastblue staining. Representative images of subcortical white matter with de-
myelination in corpus callosum (red arrows) after EAE. GA treatment restored myelination partially and sPIF 
completely compared to EAE and control brain. (C) Relative quantification of myelin density. Data presented 
as mean ± SEM. PBS (n = 5), sPIF (n = 6), GA (n = 5), Control (n = 3). sPIF: synthetic PreImplantation Factor, 
GA: glatiramer acetate, EAE: experimental autoimmune encephalomyelitis. *p < 0.05; **p < 0.01; ***p < 0.001. 
Non-parametric data were analyzed using the Mann-Whitney U test and mouse survival and the disease-free 
ratio were determined by X2 analysis. Scale: 200 µm.
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subunit alpha (Prkaca), along with Src and its substrate Dlg4, take a central role. Additionally, the most abundant 
changes induced by sPIF were Dsp (desmoplakin; reduction ~50-fold), followed by Sdc1 (syndecan-1; reduction 
~38-fold), and Calm2 (Calmodulin2; increase ~5-fold) as seen in Table 3. Notably, these proteins are associated 
with neurodegenerative and neuroinflammatory diseases24–26.
spif modulates inflammation and astrocytes. To validate the global phosphorylation changes 
induced by sPIF, we chose Sdc1 and Calm2. Notably, Sdc1 is a heparin sulfate fibroblast growth factor with 
anti-inflammatory properties27. Sdc1 knock-down results in enhanced EAE severity and impaired recovery due 
to increased immune cell recruitment to the brain27. The second chosen protein was Calm2. It is a member of 
calcium signaling, which is important during brain injury and inflammation26. In order to confirm the globally 
detected effects in the brain (Fig. 3A, Tables 2 and 3), we cultured astrocytes as they contribute to neuroinflamma-
tion in EAE28 and used sPIF treatment in increasing concentration. Additionally, we chose astrocytes for in-vitro 
testing as the astrocytes in white matter are associated with inflammation that is PKA-dependent29. In line with 
our global screening approach (Fig. 3A), sPIF increased Sdc1 expression and reduced Calm2 phosphorylation 
(Fig. 3B) confirming the detected global changes (Tables 2 and 3). Further, we performed an inflammatory chal-
lenge of the primary astrocytes and used sPIF treatment. In line with previous result12,19,20, sPIF reduced the 
proinflammatory cytokines TNFα and IL-1β while decreasing the NO production (Fig. 3C). To further con-
firm sPIF’s anti-inflammatory effect, we tested EAE mice splenocytes cultured with proteolipid protein (PLP) for 
re-activation. Again, we chose the splenocytes as these represent a communication between the immune system 
and nervous system6 and sPIF suppressed the proinflammatory cytokines IL17 and IL6 after PLP-stimulated EAE 
Figure 2. sPIF induces post-translational modifications in the EAE brains. (A) Box-and-Whisker graph of 
global normalized abundance and significantly expressed phosphoproteins. (B) The heat map shows clustered 
protein expression (rows) using unsupervised hierarchical clustering of phosphoproteins. Intensity ranges from 
highest intensity (red) to lowest (blue). Detailed protein list is presented in Tables 2 and 3. (C) Representative 
western blots of brain lysates probed with antibodies against specific (K/R)(K/R)X(s/t) and (K/R)XsX(K/R) 
phosphorylation motifs representing PKA/PKC substrates. β-Actin was used as a loading control. (D) 
Quantitative assessment of PKA/PKC kinase modulated proteins levels were quantified using beta-actin as a 
loading control. sPIF: synthetic PreImplantation Factor, EAE: experimental autoimmune encephalomyelitis. 
*p < 0.05; **p < 0.01; Data are presented as mean ± S.E.M. (one-way repeated measures ANOVA followed by 
Bonferroni’s Multiple Comparison Test, two-tailed Student’s t-test).
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derived splenocytes previously12. Here we demonstrate that sPIF increases both IL-10 and IL-4 anti-inflammatory 
cytokines secretion (Fig. 3D)12,13.
Together, sPIF reduced the magnitude of de-myelination and helped improve clinical scores in a clinically 
relevant MS animal model. These effects, at least in part, were due to global post-translational modification of 
phosphoproteins, which involved PKA/PKC signaling in combination with immune control.
Discussion
Neuroinflammation, especially inflammation leading to MS development, is a common cause of neurological 
disability16. Although, newer MS disease modifying therapies appear to reduce the magnitude of the inflamma-
tory phase of the disease, disease progression and neurodegeneration is minimally impacted. We demonstrated in 
this study sPIF’s potential to address this gap in treatment, which in part is by post-translational modification of 
phosphoproteins that are involved in PKA/PKC signaling. The specific effect on PKA/PKC signaling is intriguing 
as the effect (Fig. 2C,D) is partially divergent from previous report7. However, the spatio-temporal dynamics on 
multiple PKA/PKC subunits and the effect of a developing brain need to be accounted for30. Further, we validated 
the global phosphorylation changes (Fig. 3A, Tables 2 and 3) using Sdc1 and Calm2 in astrocytes. We chose those 
proteins due to their involvement in inflammation in the brain26,27. We chose astrocytes for in-vitro testing as 
astrocytes are contributing to neuroinflammation in MS and EAE model28,29. Finally, the PKA/PKC modulation 
as a therapeutic approach for other neurodegenerative diseases such as cerebral ischemic/stroke and Alzheimer’s 
Disease was previously demonstrated31–33. Therefore, Alzheimer’s Disease, perinatal brain injury, and MS are 
ID Gene Name
Phosphoproteins significantly reduced by sPIF but not by EAE
Arfgef2 ADP-ribosylation factor guanine nucleotide-exchange factor 2 (brefeldin A-inhibited)
Cadps Ca2+ -dependent secretion activator
Ndrg1 N-myc downstream regulated gene 1
Ablim1 actin-binding LIM protein 1
Ablim2 actin-binding LIM protein 2
Camk2b calcium/calmodulin-dependent protein kinase II, beta
Csf1r colony stimulating factor 1 receptor
Dock7 dedicator of cytokinesis 7
Dlg4 discs, large homolog 4 (Drosophila)
Pard3b par-3 partitioning defective 3 homolog B (C. elegans)
Pip5k1a phosphatidylinositol-4-phosphate 5-kinase, type 1 alpha
Kctd16 potassium channel tetramerisation domain containing 16
Prkcd protein kinase C, delta
Ttbk1 tau tubulin kinase 1
Tns1 tensin 1
Pdlim4 PDZ and LIM domain 4
Pcp2 Purkinje cell protein 2 (L7)
Rcsd1 RCSD domain containing 1
Grm5 glutamate receptor, metabotropic 5
Samhd1 hypothetical protein LOC100045969; SAM domain and HD domain, 1
Prkaca protein kinase, cAMP dependent, catalytic, alpha
Cnn3 similar to calponin 3, acidic; predicted gene 4815; calponin 3, acidic
Syn1 synapsin I
Syt12 synaptotagmin XII
Phosphoproteins significantly induced by sPIF but not by EAE
Ctnnd1 catenin (cadherin associated protein), delta 1
Pclo piccolo (presynaptic cytomatrix protein); hypothetical protein LOC100044163
Nefh similar to neurofilament protein; neurofilament, heavy polypeptide
Ttn Titin
Vezf1 vascular endothelial zinc finger 1
Phosphoproteins significantly induced by EAE but not by sPIF
Dmxl2 Dmx-like 2
Lpin1 lipin 1
Hsp90aa1 heat shock protein 90, alpha (cytosolic), class A member 1
Tet1 tet oncogene 1
Table 2. Clustering analysis of phosphoprotein differential expression. Detailed analysis of phosphoproteins 
in the brain induced after EAE and/or treatments at Time Point 3 (50 days). sPIF: synthetic PreImplantation 
Factor; EAE: experimental autoimmune encephalomyelitis.
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potential disease candidates for successful sPIF treatment7,12–15. Other diseases such as anti N-methyl-D-aspartate 
ion channel receptor (NMDAR) autoimmune encephalitis are potential candidates as well. We identified Dlg4 
and calcium/calmodulin-dependent protein kinase members (Table 2 and Fig. 3A) as PIF targets after EAE and 
these regulate NMDAR activity34,35. Together, although current evidence is derived from animal models, sPIF 
is a promising therapeutic agent to treat multiple neurodegenerative disorders especially since sPIF crosses the 
blood-brain-barrier and received a FDA Fast Track Approval for first in human trial in autoimmune hepatitis, 
which was successfully completed36.
We acknowledge that there are several limitations of this study such as the observational character of our study 
or the animal model itself. As most animal models of MS, the EAE model does not directly represent the human 
disease. However, the EAE model led to introduction of other MS drugs and is suitable to study MS pathogenesis 
and candidate therapies37. The EAE animal model results in T-cell mediated activation and differentiation into 
encephalitogenic Th1/Th17 cells38. Auto-reactive Th1 and Th17 cells and antigen presenting cells play an essential 
role in MS pathogenesis and not surprisingly IL-6 or TGF-β cytokines are detected in chronic MS brain lesions39. 
The sPIF-induced increase in IL-10 and IL-4 secretion (Fig. 3D) is in line with the decrease of pro-inflammatory 
cytokines in chronic EAE and Mycobacterium Smegmatis induced neuroinflammation models12,13. Interestingly, 
intrathecal and intranasal IL-4 treatment during the chronic phase of several EAE models reversed disease pro-
gression6. The question whether sPIF will be effective in viral models reflecting key features of MS-like inflam-
matory de-myelination is still open but beyond the scope of this manuscript. Additionally, the exact pathways 
modulated by sPIF in EAE needs further attention, although, this study offers important insights that could help 
guide further studies. sPIF has the potential to impact the inflammatory aspect(s) of MS in part by modulating 
post-translational modification of phosphoproteins and has a putative re-myelinating properties. Therefore, sPIF 
is a strong candidate for human clinical trials in MS.
Entrez Gene Canonical Name EAE vs Control EAE + sPIF vs EAE
EAE + sPIF vs 
Control
109620 Dsp 1.8582592 48.9470834 90.8832658
22138 Ttn 0.993652 45.4578046 87.1599315
20969 Sdc1 1.6684294 37.2113239 62.0345661
16678 Krt1 2.2114833 24.3724923 53.8560382
223650 Eppk1 4.7528523 6.1181544 29.0553129
100177 Zmym6 −1.002286 20.2999401 20.2373644
71752 Gtf3c2 3.7822468 5.24402904 19.8182708
224432 Scaf4 112.08234 −7.9380282 14.1083223
68760 Synpo2l −1.200038 16.5643611 13.7921068
118449 Synpo2 1.4249756 8.80237652 12.5330903
70233 Cd2bp2 122.52817 −9.8414457 12.440214
105245 Txndc5 176.12964 −16.722331 10.5241357
59006 Myoz2 1.3498843 6.8535988 9.24412972
217615 Ctage5 2.1995328 3.34714634 7.356241
194352 Trpv5 −1.137748 7.85847523 6.90149395
67228 Dph7 −1.487115 9.50958865 6.38951462
226594 Rcsd1 5.4588784 1.06107557 5.78762707
16527 Kcnk3 2.0452615 2.78275384 5.68688489
140780 Bmp2k 2.6330244 2.10780982 5.54545416
26386 Hsf4 3.250466 1.68234731 5.46401758
215476 Prr14l −1.865828 −2.8858887 −5.3889041
11947 Atp5b −2.215433 −2.6252907 −5.8208343
268373 Ppia −5.674568 −1.1228766 −6.3769652
18039 Nefl −15.53543 1.70047011 −9.1433112
19153 Prx −4.408617 −2.5637779 −11.311805
100503605 Hbb-bs −3.799876 −3.110475 −12.411454
12313 Calm2 −6.542107 −4.6028786 −30.136746
15519 Hsp90aa1 −5.915526 −6.8662554 −46.925216
Table 3. Phosphoprotein expression classified by EGAN probability analysis. Detailed analysis of 
phosphoproteins in the brain induced after EAE and/or treatments at Time Point 3 (50 days). We ranked the 
expression by sPIF effect versus control mice and only proteins that showed a 5-fold increase or decrease (or 
more) are listed. The positive numbers indicate increase (three highest are bold) and negative numbers decrease 
of phosphoprotein expression. sPIF: synthetic PreImplantation Factor; EAE: experimental autoimmune 
encephalomyelitis.
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Figure 3. sPIF modulates PKA/PKC signaling and inflammation. (A) Gene enrichment and network linkage 
analysis hypergraph of phosphoproteins created using EGAN. The hypergraph is annotated with signaling 
pathways and GO Process terms. Kinase-substrate interaction is encoded as violet edges. Enrichment 
probability is depicted by the thickness of borders, upregulation is colored red and downregulation is colored 
green. Data is represented as fold change of differentially expressed proteins in sPIF compared to EAE 
mice treated with PBS. (B,C) Validation of the global analysis using western blots. Cultured astrocytes were 
treated with sPIF (or control) in dose dependent manner. Representative western blots showing decreased 
phosphorylation of Calm2 and increased expression of Sdc1. (C) Cultured astrocytes were challenged with 
LPS/IFN and treated with sPIF or control. Using Elisa we detected reduced proinflammatory cytokines 
TNFα and IL-1β and decreased NO production after sPIF treatment. (D) EAE mice derived splenocytes 
were activated and supernatant tested for cytokines using ELISA. sPIF increases IL-10 and IL-4 levels. sPIF: 
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Materials and Methods
Animal studies. Mice. SJL mice (5–6 weeks old female) were obtained from Harlan Laboratories Ltd. 
(Israel). Mice were kept and monitored in SPF conditions with autoclaved cages. The study was conducted under 
appropriate conditions and approved by the Institutional Animal Welfare Committee of the Hebrew University of 
Jerusalem. All methods were performed in accordance with the relevant guidelines and regulations. We induced 
EAE in mice as previously described12. Briefly, SJL females (N = 7–18/group in four independent experiments) 
were immunized subcutaneously on day 0 with a 1:1 emulsion comprised of 100 μg proteolipid protein (PLP) 
(aa 139–151 peptide) and Mycobacterium tuberculosis H37R (BD Biosciences) in complete Freund’s adjuvant 
(CFA) to final volume of 2 mg/ml. At day 0 and day +2, pertussis toxin (Sigma Chemicals, St. Louis, MO) was 
administered (250 ng/mouse) intra-peritoneal (I.P.) injection. Mice were monitored daily, starting on day +6 
until sacrifice.
sPIF (0.75 mg/kg bodyweight subcutaneously), Glatiramer acetate (GA) (5 mg/kg bodyweight) or PBS was 
administered twice daily. We initiated treatment once paralysis was documented defined as score 1 and/or above. 
We continued the treatment until paralysis totally regressed (0). The treatment was started episodically again only 
when a given mouse had started to develop signs of paralysis and stopped when paralysis totally resolved.
PIF synthesis. Synthetic PIF (sPIF), proprietary fifteen-amino-acid peptide (MVRIKPGSANKPSDD), was pro-
duced using solid-phase peptide synthesis (Peptide Synthesizer, Applied Biosystems, Foster City, CA) employ-
ing Fmoc (9-fluorenylmethoxycarbonyl) chemistry12. Final purification was carried out by reversed-phase 
high-pressure liquid chromatography (HPLC), peptide identity was verified by matrix-assisted laser desorption/
ionization time-of-flight (MALDI-TOF) mass spectrometry and amino acid analysis, and the peptide was puri-
fied to >95% by HPLC, as documented by mass spectrometry was generated (Polypeptide Labs, CA). Clinical 
grade Glatiramer acetate (GA) (Teva, Israel) was received as a gift from Dr. Karousis, Hadassah Medical Center, 
Department of Neurology.
Clinical evaluation of neuroinflammation. The separation of mice to groups was randomized12. The first signs 
of paralysis appeared within a few days post-immunization which varied due to the intensity of the disease. In 
general, the clinical signs started within 6–11 days (~9) from inoculation. Mice were monitored daily and scored 
using the standard EAE six-point scale: 0–normal behavior; 1-low tail tonus; 2-hind-leg weakness; 3-hind-leg 
paralysis; 4-full paralysis; and 5-death12. In all cases, we calculated the following scores: (1) mean clinical score 
(MCS) defined as the average of the daily scores of all mice within each group. (2) mean peak paralysis scores (PP) 
defined as the average of individual scores of all mice in the group. (3) mean clinical score at end (MCE) defined 
as the average score of all mice within each group on the last day of study (day 26–50 of the experiment).
Splenocytes cultures and cytokines analysis. Method of culture and cytokine testing were previously reported12. 
Briefly, spleens from sacrificed mice from sPIF, GA, PBS-treated or naïve mice groups were harvested and their 
splenocytes isolated. Cells were cultured in DMEM medium supplemented with 10% fetal bovine serum, 2 mM 
L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin. Cells were cultured in duplicate at 5 × 106 cells/
well in presence of 4 mg/ml PLP peptides. Negative control wells were cultured without PLP peptides, whereas 
positive control wells were cultured with 2.5 μg/ml concanavalin A (ConA). After 3 days of incubation, the super-
natant was collected and the cytokine levels were determined by using FlowCytomix Mouse Th1/Th2 10plex kit 
according to the manufacturer recommendation (eBioscience).
Astrocyte cultures and measurment of inflammatory markers. Mixed astrocyte cultures were obtained as pre-
viously performed13. Briefly, cultures were prepared from 1–2 day old C57BL/6 mouse neonates with cortices 
isolated, cut into small pieces, and incubated with 2.5% Trypsin for 30 min at 37 °C. Following centrifugation, 
the tissue pellet was mechanically dissociated into single cells. Cells were plated in DMEM, high glucose +10% 
heat-inactivated fetal bovine serum +1% Penicillin/Streptomycin. After 8 days, confluent cultures undergo a 
series of shaking to remove microglia and oligodendrocyte precursor cells and the astrocytes are trypsinized 
and replated. Purity of the primary astrocytes was determined by immunofluorescence staining with GFAP and 
GLAST (Over 95% positive cells). The inflammatory challenge was performed using LPS (10 µg/ml) and IFN-g 
(3 ng/ml) with or without sPIF (100 nM) for 24 hours. The secretion of TNF-α and IL-1β was determined in tissue 
supernatants using ELISA kits (Abcam: ab100747 and ab100705) according to manufacturer’s instruction. The 
production of NO by astrocytes was analyzed by indirect measurement of nitrite concentration using the colori-
metric Griess assay (Sigma-Aldrich G4410) according to manufacturer’s instruction. A standard curve of sodium 
nitrite was used for calibration.
Histological analysis. Brain tissue samples (sPIF, GA, PBS and naïve mice) were fixed in 4% neutral-buffered for-
malin, embedded in paraffin and sectioned into 7 μm slices. Slides were rinsed in DDW, counterstained in Cresyl 
violet and Luxol Fast Blue, dehydrated in ethanol and xylene, and mounted with Eukitt (Sigma-Aldrich, St. Louis, 
MO)13. We acquired images using a BX51 microscope (Olympus, Tokyo, Japan) with a 20× or 40× objective and 
equipped with a digital camera. An independent observer acquired sections visual field by visual field without 
synthetic PreImplantation Factor, GA: glatiramer acetate, EAE: experimental autoimmune encephalomyelitis. 
LPS: Lipopolysaccharides, IFN: Interferon γ. *p < 0.05; **p < 0.01; ***p < 0.001. Data are presented as 
mean ± S.E.M. (one-way repeated measures ANOVA followed by Bonferroni’s Multiple Comparison Test, two-
tailed Student’s t-test).
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overlapping per hemisphere and animal for each specific staining blinded to the experimental conditions. The 
region of interest (ROI) was the corpus callosum13. To asses myelin loss (MBP immunostaining) we measured the 
percentage of positive MBP staining (area) in the ROI as described previously22,40.
Tissue lysate preparation and phosphoproteome analysis. PTMScan phosphorylation analysis was performed on 
mouse brain samples as previously described23. Mice brain tissue (PBS n = 5, sPIF n = 6, naïve untreated control 
n = 3) obtained from the chronic EAE experiment on day 50, was deeply frozen. An aliquot of brain tissue extracts 
was removed for protein concentration determination with BCA assay (Thermo Fischer). We placed 20 mg of 
mouse tissue extract per condition in 5 ml urea lysis buffer reduced with 4.5 mM DTT for 30 min at 55 °C, alky-
lated with iodoacetimide (0.095 g per 5 mL H2O) for 15 min at room temperature in the dark. We diluted samples 
1:4 with 20 mM HEPES pH 8.0 and digested overnight with 50 µg LysC (Wako, #129–02541) per 5 mg cellular 
protein. We normalized soluble protein amounts for each sample prior to digestion to ensure equal protein input 
for all samples. We acidified the digested peptide lysates with 1% TFA and desalted the peptides over 360 mg SEP 
PAK Classic C18 columns (Waters, #WAT051910). We eluted the peptides with 40% acetonitrile in 0.1% TFA, 
dried under vacuum, and stored at −80 °C. For Phosphoprotein Immunoprecipitation we used following setup 
as previously performed {Mueller, 2015 #17}. PTMScan motif antibodies: Akt (#9614 & #10001), PKA (#9624), 
PKC (#2261), PKD (#4381), CDK (#2324), AMPK (#5759), ATM/ATR (#6966 & #9607), CK (#8738), PDK1 
(#9634), MAPK (#2325), tP (#8134), tPE (#3004), PLK (#5243), tXR (#8139), 14-3-3 (#9442) were combined and 
conjugated to 40 ul of Protein A agarose (Roche) overnight at 4 °C. Lyophilized peptides were re-suspended in 
MOPS IAP buffer (50 mM MOPS pH 7.2, 10 mM KH2PO4, 50 mM NaCl) and centrifuged 5 min at 12,000 RPM in 
a MiniSpin microcentrifuge (Eppendorf). Supernatants were mixed with PTMScan Reagent-Bead slurries 2 hours 
at 4 °C. Beads were pelleted by centrifugation 30 seconds at 5,400 RPM in a MiniSpin microcentrifuge at 4 °C. 
Beads were washed twice with 1 mL MOPS IAP buffer and four times with 1 mL water (Burdick and Jackson). 
Peptides were eluted from beads with 0.15% TFA (sequential elutions of 65 µL followed by 55 µL, 10 min each at 
room temperature). Eluted peptides were desalted over tips packed with Empore C18 (Sigma) and eluted with 
40% acetonitrile in 0.1% TFA. Eluted peptides were dried under vacuum. LysC digested peptides were subjected 
to a second, in-solution trypsin digest using 250 ng of sequencing grade trypsin (Promega) in 50 mM ammonium 
bicarbonate/5% acetonitrile for 2 hours at 37 °C. Samples were acidified with TFA and re-purified over C18 tips as 
before. We used following MS Parameter Settings: MS Run Time 90 min, MS1 Scan Range (300.0–1500.00), Top 
20 MS/MS (Min Signal 500, Isolation Width 2.0, Normalized Coll. Energy 35.0, Activation-Q 0.250, Activation 
Time 20.0, Lock Mass 371.101237, Charge State Rejection Enabled, Charge State 1+ Rejected, Dynamic Exclusion 
Enabled, Repeat Count 1, Repeat Duration 35.0, Exclusion List Size 500, Exclusion Duration 40.0, Exclusion Mass 
Width Relative to Mass, Exclusion Mass Width 10ppm). Real time recalibration of mass error was performed 
using lock mass with a singly charged polysiloxane ion m/z = 371.101237.
LC-MS/MS analysis. We re-suspended the immunoprecipitated peptides in 0.125% formic acid and separated 
them on a 10 cm × 75 μm PicoFrit capillary column packed with Magic C18 AQ reversed-phase resin. The col-
umn was developed with a 120-minute linear gradient of acetonitrile in 0.125% formic acid delivered at 280 nL/
min. Each sample was split. We run analytical replicate injections to increase the number of identifications and 
additionally to provide metrics for analytical reproducibility. Replicate injections were run non-sequentially to 
reduce artifact-associated changes in peptide abundance due to changes in instrument performance over time. 
One replicate of each sample was injected, then the second replicate in reverse order. Tandem mass spectra were 
collected in a data-dependent manner with an LTQ-Orbitrap Velos mass spectrometer running XCalibur 2.0.7 
SP1 using a top-twenty MS/MS method, a dynamic repeat count of one, and a repeat duration of 30 sec. We used 
following LC-MS2 PRIMARY Data Analysis: MS/MS spectra were evaluated using SEQUEST, and the Core plat-
form from Harvard University23. Files were searched against the NCBI Mus musculus FASTA database, release 
date 06/28/2011. A mass accuracy of +/−50 ppm was used for precursor ions and 1 Da for product ions. We 
limited the enzyme specificity to LysC/trypsin, with at least one LysC or tryptic (K- or R-containing) terminus 
required per peptide and up to four mis-cleavages allowed. Cysteine carboxamidomethylation was specified as 
a static modification. Oxidation of methionine residues was allowed. Phosphorylation was allowed on serine, 
threonine, and tyrosine residues. We included reverse decoy databases for all searches to estimate false discovery 
rates and filtered using a 1% FDR in the Linear Discriminant module of Core. We further narrowed the results by 
mass accuracy based on clustering of forward and reverse assignments in Xcorr versus mass error plots. Typically, 
forward database assignments cluster within −/+5 ppm of calculated m/z, so results were limited to peptides 
that fall within that range. We used a larger mass error range (−/+50 ppm) for the searches to allow for identifi-
cation even if the lock mass signal was not adequate for accurate mass calibration. We manually filtered peptides 
using reagent-specific criteria. For each antibody reagent results were filtered to include only phosphoproteins 
matching the sequence motif(s) targeted by the antibodies included. All quantitative results were generated using 
Skyline Version 3.1 to extract the integrated peak area of the corresponding peptide assignments. Extracted ion 
chromatograms for peptide ions that changed in abundance between samples were manually reviewed to ensure 
accurate quantitation in Skyline 3.1 or XCalibur software (version 2.0.7 SP1, Thermo Scientific). We normalized 
peak areas using a log2 median normalization strategy as previously described23. To identify proteins with statisti-
cally significant changes in experimental groups (PBS treated EAE mice, sPIF treated EAE mice and intact mice), 
we used the label-free quantification (LFQ) intensities. LFQ values were normalized and ratios between EAE mice 
and control mice, sPIF treated EAE mice and EAE mice, as well as sPIF treated EAE mice to control estimated.
Differential phosphoprotein expression analysis. Peptide abundances among technical replicates were combined, 
log2-transformed, normalized and converted to protein abundances with the ZRollup method implemented in 
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InfernoRDN (http://omics.pnl.gov/software/infernordn). Only proteins with two or more unique peptides were 
retained for ANOVA analysis (P-values < 0.05 and q-values to control the false discovery rate below 0.04 in mul-
tiple testing41. Unsupervised hierarchical clustering was used for grouping both individual experimental samples 
and ZRollup estimated protein abundances. Heatmap with top (samples) and left (proteins) dendrogram was 
produced (Fig. 3B). Proteins were clustered using Agglomeration Average method applying Euclidean distance 
metric, while samples were clustered using Complete Linkage method applying Euclidean distance metric. We 
further used EGAN: Exploratory Gene Association Networks (http://akt.ucsf.edu/EGAN/) on ANOVA filtered 
proteins for hypergraph visualization of proteins and meta-data enrichment analysis (Gene Ontology annota-
tion, KEGG, PANTHER signaling pathways). Protein expression fold change between treatment groups were 
calculated and fed to EGAN. Additionally, an extra Kinase-substrate interaction node linking file was produced, 
using information from PhoshpositePlus database (http://www.phosphosite.org/, CellSignaling, MA, US). The 
Analysis of phosphosite correlation to kinase/phosphatase and phosphor-peptide associations was used. Peptide 
and protein expression was analyzed SELPH platform (Systematic Extraction of Linked Phospho-Interactions) for 
correlation analysis of phospho-sites to extract kinase/phosphatase and phospho-peptide associations and link 
this data to GO and pathway enrichment42.
Verification studies. For verifications of the LC-MS/MS results we performed Western blot analysis in astro-
cytes. Mouse brain mixed astrocytes were isolated and were treated with sPIF at given concentration for 24 hours. 
The expression of Syndecan-1 and CALM2 was determined using Western blot analysis. Rabbit anti-syndecan 
1 (Abcam: ab34164, USA) was used at a dilution of 1:3000 and mouse anti-CALM2 (Abcam: ab2860, USA) and 
phospho anti-CALM2 (Abcam: ab61001, USA), and actin (Abcam: ab8227, USA) were used at a dilution of 
1:1000. Western blot analysis of the protein samples was performed as previously described7. Briefly, 20–30 µg 
aliquots of total protein were electrophoresed, transferred onto PVDF membrane and probed with the specific 
antibodies. Detection of HRP-conjugated antibodies was performed using SuperSignal (Pierce, Rockford, IL). 
Equal protein loading was examined using Ponceau S staining or probing the membrane with anti-actin antibody.
For analysis of the individual phospho-peptide sequences, phosphorylation sites, peptide abundances accord-
ing to mice treatment scenarios, corresponding protein PPIs, we carried out Western Blotting as well. Protein 
concentrations were measured by Bradford Assay and 25 µg of total protein was run in each lane for western blot-
ting. Western blots were developed using a LI-COR Odyssey NIR (near infrared) imaging system. Normalized 
quantitation was performed to compare relative abundance of individually detected proteins in EAE model, sPIF 
treated EAE model and intact (PBS-treated) scenarios.
Statistical analysis. Non-parametric data were analyzed using the Mann-Whitney U test. Mouse survival and 
the disease-free ratio at the end of the study were determined by X2 analysis. P < 0.05 was considered statistically 
significant. For other analyses comparison among the treated groups were carried initially using ANOVA fol-
lowed by t test to determine significance set at p < 0.05.
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